Pilot study evaluating salivary bile acids as a diagnostic biomarker of laryngopharyngeal reflux
Diseases of the Esophagus · 2024
DOI: 10.1093/dote/doae021 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diseases of the Esophagus, 2024. Verfasst von Amanda J Krause und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Gastroenterology & Hepatology, University of California San Diego, San Diego, CA, USA. Hauptthemen laut MEDLINE: Bile Acids and Salts, Biomarkers, Saliva, Laryngopharyngeal Reflux. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIH HHS, Ironwood Pharmaceuticals.
Abstract (Originalsprache)
Bile acids in refluxate contribute to esophageal and laryngeal symptoms and are quantifiable. The aim of this study was to compare salivary bile acid concentrations across healthy controls and symptomatic patients (esophageal or laryngeal) with or without objective gastroesophageal reflux disease (GERD). This prospective study enrolled adults into three groups: esophageal symptoms (heartburn, regurgitation, chest pain); laryngeal symptoms (cough, throat clearing, sore throat, dysphonia); and controls. Symptomatic patients primarily underwent prolonged wireless reflux monitoring off acid suppression and were categorized as symptomatic no GERD (acid exposure time <4%) or esophageal/laryngeal symptoms with GERD (acid exposure time ≥4%). Controls did not undergo reflux monitoring nor upper endoscopy. Saliva samples were provided for bile acid analysis via ultraperformance liquid chromatography tandem mass spectrometry. Thirty-five participants were enrolled (mean age 47.4 years [SD 18.9], 16 [46%] male), including 10 controls and 25 symptomatic: 9 no GERD, 5 esophageal symptoms + GERD, and 11 laryngeal symptoms + GERD. Total salivary bile acids were highest in the laryngeal symptoms + GERD group (24.2 nM [SD 24.7]) compared to other groups (controls: 5.8 [6.0], P = 0.03; symptomatic no GERD: 3.1 [4.4]; P < 0.01; esophageal symptoms + GERD: 7.1 [7.1], P = 0.10). Bile acids were elevated in 45% (5/11) of the laryngeal symptoms + GERD group compared to 0% of the other three groups (P < 0.01). Salivary bile acids were higher among patients with laryngeal symptoms and objective GERD versus other groups. Salivary bile acids are a quantifiable biomarker with diagnostic potential for laryngopharyngeal reflux.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Division of Gastroenterology & Hepatology, University of California San Diego, San Diego, CA, USA.
- Clinical Development Department, Ironwood Pharmaceuticals, Boston, MA, USA.
ORCID-Profile: Amanda J Krause, Rena Yadlapati
Förderung
- NIDDK NIH HHS
- NIH HHS
- Ironwood Pharmaceuticals
- National Institutes of Health
- NIH
Zitieren
APA
Krause, A. J., Greytak, M., Kessler, M., & Yadlapati, R. (2024). Pilot study evaluating salivary bile acids as a diagnostic biomarker of laryngopharyngeal reflux. Diseases of the Esophagus. https://doi.org/10.1093/dote/doae021
Vancouver
Krause AJ, Greytak M, Kessler M, Yadlapati R. Pilot study evaluating salivary bile acids as a diagnostic biomarker of laryngopharyngeal reflux. Diseases of the Esophagus. 2024. doi:10.1093/dote/doae021
BibTeX
@article{Krause2024,
author = {Krause, Amanda J and Greytak, Madeline and Kessler, Marco and Yadlapati, Rena},
title = {Pilot study evaluating salivary bile acids as a diagnostic biomarker of laryngopharyngeal reflux},
journal = {Diseases of the Esophagus},
year = {2024},
doi = {10.1093/dote/doae021}
}
EUVIMED